Gestational choriocarcinoma

Gestational choriocarcinoma is a highly malignant form of gestational trophoblastic neoplasia (GTN) that arises from trophoblastic tissue following a gestational event, most commonly a complete hydatidiform mole, but also after a normal pregnancy, ectopic pregnancy, or spontaneous abortion. It is characterized by abnormal, aggressive proliferation of both cytotrophoblast and syncytiotrophoblast cells without the formation of chorionic villi. The tumor is highly vascular and has a strong tendency to invade the uterine wall and metastasize early via hematogenous spread to distant organs, most commonly the lungs, brain, liver, and vagina. Key symptoms include abnormal vaginal bleeding following any gestational event, a persistently elevated or rising serum beta-human chorionic gonadotropin (β-hCG) level, and an enlarged uterus. Patients with metastatic disease may present with hemoptysis, neurological symptoms (headaches, seizures), or hepatic hemorrhage depending on the sites of spread. Theca lutein ovarian cysts may also be present due to high hCG levels. Despite its aggressive nature, gestational choriocarcinoma is one of the most curable solid tumors. Treatment is based on risk stratification using the FIGO/WHO scoring system. Low-risk disease is typically treated with single-agent chemotherapy (methotrexate or actinomycin D), achieving cure rates exceeding 95%. High-risk or metastatic disease requires multi-agent chemotherapy regimens such as EMA-CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine), with cure rates of approximately 80-90%. Serum β-hCG serves as a reliable tumor marker for monitoring treatment response and detecting recurrence. Hysterectomy may be considered in select cases, particularly in patients who have completed childbearing or have chemotherapy-resistant uterine disease.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Gestational choriocarcinoma